



November 21, 2024

Dear Rett Syndrome Community,

Earlier this week, we shared that a girl who received the 3E15 vg dose of NGN-401 gene therapy in our ongoing Phase 1/2 clinical trial for Rett syndrome was in critical condition. Tragically, she has passed away following complications from a rare and life-threatening hyperinflammatory syndrome associated with systemic exposure to high doses of AAV gene therapies. The entire Neurogene team is sending our deepest condolences to her family and loved ones and wishing them strength as they navigate life without their precious child. While this is a somber moment for everyone in the community, Neurogene's mission to bring forward new treatments to help families affected by Rett syndrome is unwavering.

We want to assure you that the plans for the NGN-401 clinical trial that we communicated in our letter on November 18 have not changed. We will continue to move the NGN-401 program forward at the 1E15 vg dose in pediatrics, adolescents and adults. As previously shared, we are updating the clinical trial protocol to remove the 3E15 vg dose.

We want to reiterate our commitment to patient safety. In clinical trial participants dosed with the 1E15 vg dose of NGN-401, there have been no treatment-related serious adverse events (SAEs) and all treatment-related adverse events (AEs) have been mild. Rare hyperinflammatory syndrome has only been reported in the field of AAV gene therapy at doses higher than our 1E15 vg dose. In addition, we resolve to share key learnings about this rare immune response to advance the science and safety of AAV gene therapy.

Neurogene is motivated by the improvements observed in multiple aspects of Rett syndrome in those who received the 1E15 vg dose and has the resources to advance NGN-401 forward for the Rett syndrome community.

Sincerely,

Rachel McMinn, Ph.D.

Founder and Chief Executive Officer

For more information, please refer to our prior letters to the community at <https://www.neurogene.com/patients-and-families/about-rett-syndrome/>.

NGN-401 is not approved by any regulatory agency for use outside of the clinical trial.